For decades, colorectal cancer treatment has followed the same playbook: surgeons remove the tumor, then patients endure months of chemotherapy hoping to catch any remaining cancer cells. Yet even with this aggressive approach, about one in four patients see their disease return within three years. A new trial suggests we’ve had the timing all wrong.
A Radical Rethinking of Treatment Timing
According to Science Daily, researchers at UCL discovered something unexpected: what if we hit tumors with immunotherapy before the scalpel, rather than after? In a clinical trial involving 32 patients with high-risk colorectal cancers, participants received only nine weeks of pembrolizumab prior to surgery, skipping the traditional post-operative chemotherapy entirely.
The findings defy conventional wisdom. After nearly three years of observation, these patients showed an astonishing zero recurrence rate. Even more striking: the approach worked regardless of whether scans showed complete tumor elimination or whether microscopic cancer traces remained. None progressed.
Why This Matters for Specific Patients
The trial focused on patients with MMR-deficient, microsatellite-instability-high cancers, a distinct genetic subtype representing roughly 10-15% of colorectal cancers, or approximately 2,000-3,000 new UK cases annually. In this population, initial scans revealed that 59% achieved complete remission after the immunotherapy-surgery combination.
The broader context: colorectal cancer kills thousands annually and ranks as the UK’s fourth most prevalent malignancy. Survival outcomes vary dramatically by stage, catching disease early means 90% five-year survival, but advanced presentations drop to just 10%.
The Blood Test Revolution
Beyond clinical outcomes, the research team developed something potentially more transformative: blood-based diagnostics that identify residual tumor DNA. These tests act as an early warning system, distinguishing patients likely to remain disease-free from those at higher risk of recurrence.
Professor Marnix Jansen notes that immune profiling of tumor tissue before treatment begins can also predict response. This moves cancer care toward precision medicine, doctors tailoring intensity based on individual biology rather than one-size-fits-all protocols.
Real People, Real Results
Christopher Burston’s journey illustrates the human stakes. The 73-year-old Dorset resident underwent routine screening in early 2023 when blood detection flagged a concerning result. Colonoscopy confirmed stage three colorectal cancer, serious enough to warrant aggressive intervention.
Instead of the conventional surgery-then-chemotherapy sequence, he joined the research program. Three immunotherapy infusions over nine weeks preceded his May 2023 surgery. The result? Doctors described it as the tumor having “melted away.” Recovery proved unremarkable, minimal complications, quick return to normal activities. Nearly three years forward, he remains cancer-free.
“My main problem now is age, not cancer,” he reflected, capturing the profound difference this treatment represents.
Rethinking Standard Care
The implications ripple across oncology. If pre-surgical immunotherapy delivers superior durability compared to post-surgical chemotherapy, hospitals worldwide may need to reconsider their protocols. The traditional approach assumes surgery must come first, but immunotherapy may work better as a frontline assault, priming the immune system before physical tumor removal.
The research team presented these findings at the 2026 American Association for Cancer Research conference, signaling serious scientific validation.
The Path Forward
While these results apply specifically to one genetic subtype, the underlying principle, using immunotherapy strategically before surgery, could reshape treatment across multiple cancer types. The personalized blood tests offer a mechanism to monitor response in real-time, potentially sparing patients’ unnecessary toxicity while intensifying care for those needing it.
For the estimated 44,000 British patients annually receiving colorectal cancer diagnoses, particularly younger populations experiencing rising incidence, this represents genuine hope—not just improved statistics, but the possibility of returning to normal life cancer-free.
